Transaction overview
Nathan L. Mata, Chief Scientific Officer at BELITE BIO, INC (NASDAQ:BLTE), sold a total of 1,000 American depositary shares on April 17, 2026, for aggregate proceeds of $161,629. The shares were disposed of at prices between $158.4563 and $163.325 per ADS. These dispositions were carried out under a Rule 10b5-1 trading plan that Mr. Mata established on December 10, 2025.
Share count and structure
Following the sales, Mr. Mata directly holds 13,666 American depositary shares in Belite Bio. Each American depositary share represents one ordinary share of the issuer.
Stock performance and valuation context
Belite Bio's shares have risen 193% over the past year and are currently trading at $165.43. According to an InvestingPro analysis cited by market sources, the stock is assessed as slightly undervalued relative to its Fair Value. That same InvestingPro resource offers 11 additional tips on BLTE and provides context around the company’s reported $6.51 billion market valuation.
Company liquidity and planned spend
Separately, Belite Bio reported year-end liquidity comprising $353 million in cash and $420 million in investments, which Benchmark characterizes as providing more than two years of operating runway. The company has outlined plans to spend $150 million on research and development and $250 million on sales and marketing over the next four years.
Clinical results and analyst reactions
Belite Bio's Phase 3 DRAGON trial of tinlarebant for Stargardt disease achieved its primary efficacy endpoint, delivering a 35.7% reduction in the rate of macular lesion growth. This result has prompted several firms to revisit their assessments: H.C. Wainwright reiterated a Buy rating and increased its price target to $200; Benchmark raised its target to $217; and Mizuho reiterated an Outperform rating with a $223 price target. These analysts specifically cited the positive DRAGON trial results in their updated views.
Regulatory timing
Mizuho noted a refined timeline for the New Drug Application submission for tinlarebant, with the NDA now expected in the second quarter of 2026 and potential approval targeted for the first quarter of 2027. The company’s actions and analyst commentary underscore a strategic focus on advancing tinlarebant through the regulatory pathway.
Contextual note
The insider sale occurred amid the company’s notable clinical and financial developments. The sale was executed under an established 10b5-1 plan; after the transaction, Mr. Mata retains ownership of 13,666 ADS. The company’s liquidity position and budgeted allocations for R&D and sales and marketing have been explicitly stated by Benchmark and the company, and analysts have adjusted price targets in response to the Phase 3 results.